Here’s what to consider. Pfizer’s JN.1 booster (and Moderna’s, though the TGA has not approved this one at this stage) is based on mRNA technology. This technology instructs our cells to ...

This action gives people ages 18 years and older the option to receive a Novavax monovalent booster instead of an updated (bivalent) Pfizer-BioNTech or Moderna booster if they have completed ...

Moderna's chief executive. He stressed however that the mRNA-1273.214 candidate – which combines the current SpikeVax booster with an Omicron-specific candidate – is the company's lead ...

On Monday, Piper Sandler adjusted its outlook on Moderna (NASDAQ:MRNA) shares, lowering the price target to $69 from the previous $115, while maintaining an Overweight rating on the stock.

Heading into Moderna’s (Nasdaq ... lost out on a few different things here and it’s very much become a show-me story for how well can they contract. How competitive are they going to be ...

A negative legal outcome could derail my thesis and force me to reassess my strategy. I intend to focus on the implications of this lawsuit for Moderna in the near term, as well as their position ...

Can You Drink Alcohol Before a COVID Booster? There's no guidance on drinking alcohol before getting a COVID booster or vaccine. Research on the Moderna ... on your arm near where you received ...

There's one big difference though - Pfizer is seeking a green light for second booster dose of Comirnaty for people aged 60 and over and those in high-risk groups, while Moderna is going for a ...

On Monday, Piper Sandler adjusted its outlook on Moderna (NASDAQ:MRNA) shares, lowering the price target to $69 from the previous $115, while maintaining an Overweight rating on the stock. The ...

“It’s great to feel that one go in, especially this important one. “Definitely a confidence booster for me.” Miromanov’s story is one of perseverance. Never drafted, he’s had to ...

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...

On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal Phase 3 trial of V940 (mRNA-4157). V940 is an investigational ...